Michael John Harkins is VP at GenMark Diagnostics, Inc. (GNMK). They have made 6 open-market trades across 1 company since 2020, most recently 2021-04-22.
CIK 0001776613
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GNMK | 143,611 | $3.5M |
Shares reported on the most recent Form 4, priced at the 2021-03-01 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GNMK | SELL | 2021-02-26 | 2021-03-01 | $17.03 | $422K | -3.3% | +25.2% | N/A |
| GNMK | SELL | 2021-01-27 | 2021-01-29 | $14.06 | $16K | +22.1% | +37.9% | N/A |
| GNMK | SELL | 2021-01-25 | 2021-01-25 | $14.22 | $209K | -6.4% | +24.0% | N/A |
| GNMK | SELL | 2020-10-27 | 2020-10-29 | $11.34 | $12K | -0.4% | +7.9% | +8.3% |
| GNMK | SELL | 2020-07-28 | 2020-07-29 | $17.30 | $18K | -8.1% | -22.3% | -30.3% |
| GNMK | SELL | 2020-04-29 | 2020-05-01 | $11.64 | $48K | -0.3% | -15.7% | +51.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.